WVP
SRPT icon

Worth Venture Partners’s Sarepta Therapeutics SRPT Stock Holding History

Worth Venture Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-70,600
Closed -$417K – 78
2024
Q1 		$417K Buy
70,600
+5,200
+8% +$637K 2.77% 11
2023
Q4 		$238K Buy
65,400
+54,200
+484% +$5.2M 0.13% 89
2023
Q3 		$171K Buy
+11,200
New +$1.27M 0.1% 110

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Worth Venture Partners's SRPT Position: Q1 2024 in Review

Worth Venture Partners sold out of Sarepta Therapeutics (SRPT) in Q1 2024, closing a stake of 5,400 shares — an estimated $661K sold.

Worth Venture Partners first reported a position in SRPT in Q3 2023 and held it in 2 quarters. The position peaked at $885K in Q3 2023. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

  • Worth Venture Partners reported no remaining Sarepta Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Worth Venture Partners sold 5,400 Sarepta Therapeutics shares in Q1 2024, an estimated $661K.
  • Worth Venture Partners first reported a position in Sarepta Therapeutics in Q3 2023 and held it in 2 quarters.
  • Worth Venture Partners's Sarepta Therapeutics position peaked at $885K in Q3 2023.
  • 414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on Worth Venture Partners's 13F filing for Q1 2024, filed 13 May 2024.